ThePeptideGuide.uk LogoNavigation

Educational purposes only. Not medical advice. Consult healthcare professionals before use.

Growth Hormone
Preclinical

Fragment 176-191

Fragment 176-191

Also known as: HGH Fragment 176-191, HGH Frag, GH Frag

Overview

Key Facts

Primary Goal: The C-terminal fragment of human growth hormone representing amino acids 176-191

The C-terminal fragment of human growth hormone representing amino acids 176-191. This region is responsible for the fat-metabolizing properties of GH and has been shown to promote lipolysis without the anabolic or diabetogenic effects of full-length GH. Half-Life 15-20 minutes Typical Dose 250–500 mcg Frequency 1-2 times daily, fasted Cycle Length 8-16 weeks

Dosing Information

Half-Life

15-20 minutes

Typical Dose

250–500 mcg

Frequency

1-2 times daily, fasted

Cycle Length

8-16 weeks

Administration Routes:

subcutaneous

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F) or -20°C (-4°F) for long-term
DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)
Duration2-4 weeks

Research Summary

Preclinical

HGH Fragment 176-191 was identified through structure-function studies of growth hormone that mapped the lipolytic activity to the C-terminal region. In vitro and animal studies demonstrate it promotes fat oxidation at a rate 12.5 times greater than unmodified GH without affecting carbohydrate metabolism. It is primarily used in research settings focused on obesity and metabolic syndrome.

Frequently Asked Questions

Common questions about Fragment 176-191

UK-Specific Information

Exclusive data points and guidance for UK residents using Fragment 176-191

UK Lab Testing

US Lab Testing

Recommended labs: Quest Diagnostics, LabCorp ($120-$200 for peptide safety panel)

Why this matters: UK-specific lab testing guidance not available on US competitor sites

Commonly Stacked With